Cranfield Health, Cranfield University, Cranfield, Bedfordshire, UK.
Anal Chem. 2012 Jul 17;84(14):5898-904. doi: 10.1021/ac300278p. Epub 2012 Jun 25.
Early detection of cancer is vital for the successful treatment of the disease. Hence, a rapid and sensitive diagnosis is essential before the cancer is spread out to the other body organs. Here we describe the development of a point-of-care immunosensor for the detection of the cancer biomarker (total prostate-specific antigen, tPSA) using surface plasmon resonance (SPR) and quartz crystal microbalance (QCM) sensor platforms in human serum samples. K(D) of the antibody used toward PSA was calculated as 9.46 × 10(-10) M, indicating high affinity of the antibody used in developing the assay. By performing a sandwich assay using antibody-modified nanoparticles concentrations of 2.3 ng mL(-1) (Au, 20 nm) and 0.29 ng mL(-1) (8.5 pM) (Au, 40 nm) tPSA in 75% human serum were detected using the developed assay on an SPR sensor chip. The SPR sensor results were found to be comparable to that achieved using a QCM sensor platform, indicating that both systems can be applied for disease biomarkers screening. The clinical applicability of the developed immunoassay can therefore be successfully applied to patient's serum samples. This demonstrates the high potential of the developed sensor devices as platforms for clinical prostate cancer diagnosis and prognosis.
癌症的早期检测对于成功治疗该疾病至关重要。因此，在癌症扩散到其他身体器官之前，快速、灵敏的诊断是必不可少的。在这里，我们描述了一种基于表面等离子体共振（SPR）和石英晶体微天平（QCM）传感器平台的即时检测免疫传感器的开发，用于检测人血清样本中的癌症生物标志物（总前列腺特异性抗原，tPSA）。用于 PSA 的抗体的 K(D)值计算为 9.46×10(-10) M，表明用于开发该测定法的抗体具有高亲和力。通过使用抗体修饰的纳米粒子进行三明治测定法，在 75%的人血清中检测到浓度为 2.3 ng mL(-1)（Au，20 nm）和 0.29 ng mL(-1)（8.5 pM）（Au，40 nm）的 tPSA，使用开发的 SPR 传感器芯片上的测定法。SPR 传感器的结果与使用 QCM 传感器平台获得的结果相当，表明这两种系统都可用于疾病生物标志物筛选。因此，所开发的免疫测定法的临床适用性可成功应用于患者的血清样本。这表明所开发的传感器设备作为临床前列腺癌诊断和预后的平台具有很高的潜力。
